Interesting and I did note this: In April 2024, we received the appropriate sales approvals by the FDA, and we expect the marketing will be done with local partners who have the relevant abilities and connections in each territory such partners will ask to sell the products. Since each country has its specific healthcare system, a local partner (one or more) will be chosen to address the specific market needs in terms of regulation, technical support, etc. Pricing will be determined by the local partner, taking into account all overhead expected costs, regulation requirements, and reimbursement methods.

We intend to establish sales and marketing structures and strategic partnerships in the United States, U.K., and Europe to support all of our product candidates.

The target market for our PressureSafe device is relevant healthcare settings (i.e., hospitals, senior care facilities, home care companies, etc.), nursing homes, and a growing segment of long-term home care caregivers. Towards that end, in the third quarter of 2022, we began preparations in anticipation of the commercialization of PressureSafe in the United States in 2024. A distribution agreement was entered into with PI Prevention Care LLC, a newly formed entity focused on marketing to the senior care facility, hospital, and homecare markets. The Distributor, which received exclusive rights for PressureSafe distribution across the United States, includes personnel who have many years of experience in addressing and responding to the needs of these types of organizations. Under the terms of the Agreement which were publicly disclosed, to maintain exclusivity, the Distributor is obligated to comply with minimum purchase requirements of the device and accompanying disposables.